{"count": 47, "results": [{"_id": "37886137", "pmid": 37886137, "pmcid": "PMC10599680", "title": "Effect of eucalyptol on matrix metalloproteinase-9 and its tissue inhibitor in hypertensive rats", "journal": "Bioinformation", "authors": ["Murad H"], "date": "2023-05-31T00:00:00Z", "doi": "10.6026/97320630019562", "meta_date_publication": "2023", "meta_volume": "19", "meta_issue": "5", "meta_pages": "562-564", "score": 50266.137, "text_hl": "Moreover, its combination with @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ exerted more significant effects compared to each drug alone. ", "citations": {"NLM": "Murad H. Effect of eucalyptol on matrix metalloproteinase-9 and its tissue inhibitor in hypertensive rats Bioinformation. 2023;19(5):562-564. PMID: 37886137", "BibTeX": "@article{37886137, title={Effect of eucalyptol on matrix metalloproteinase-9 and its tissue inhibitor in hypertensive rats}, author={Murad H}, journal={Bioinformation}, volume={19}, number={5}, pages={562-564}}"}}, {"_id": "36376029", "pmid": 36376029, "title": "Role of lisinopril in the therapeutic management of cardiovascular disease by targeting microtubule affinity regulating kinase 4: molecular docking and molecular dynamics simulation approaches.", "journal": "J Biomol Struct Dyn", "authors": ["Atiya A", "Alsayari A", "Bin Muhsinah A", "Almaghaslah D", "Bilgrami AL", "Abdulmonem WA", "Alorfi NM", "DasGupta D", "Ashraf GM", "Shamsi A", "Shahwan M"], "date": "2022-11-14T00:00:00Z", "doi": "10.1080/07391102.2022.2143425", "meta_date_publication": "2022 Nov 14", "meta_volume": "", "meta_issue": "", "meta_pages": "1-7", "score": 50258.523, "text_hl": "Role of @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ in the therapeutic management of @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@cardiovascular disease@@@ by targeting @GENE_MARK4 @GENE_57787 @@@microtubule affinity regulating kinase 4@@@: molecular docking and molecular dynamics simulation approaches.", "citations": {"NLM": "Atiya A, Alsayari A, Bin Muhsinah A, Almaghaslah D, Bilgrami AL, Abdulmonem WA, Alorfi NM, DasGupta D, Ashraf GM, Shamsi A, Shahwan M. Role of lisinopril in the therapeutic management of cardiovascular disease by targeting microtubule affinity regulating kinase 4: molecular docking and molecular dynamics simulation approaches. J Biomol Struct Dyn. 2022 Nov 14;():1-7. PMID: 36376029", "BibTeX": "@article{36376029, title={Role of lisinopril in the therapeutic management of cardiovascular disease by targeting microtubule affinity regulating kinase 4: molecular docking and molecular dynamics simulation approaches.}, author={Atiya A and Alsayari A and Bin Muhsinah A and Almaghaslah D and Bilgrami AL and Abdulmonem WA and Alorfi NM and DasGupta D and Ashraf GM and Shamsi A and Shahwan M}, journal={J Biomol Struct Dyn}, pages={1-7}}"}}, {"_id": "38262719", "pmid": 38262719, "title": "Delayed drug-induced liver injury (DILI) and flare of chronic plaque psoriasis secondary to lisinopril use.", "journal": "BMJ Case Rep", "authors": ["Jarman GL", "Webb GJ"], "date": "2024-01-23T00:00:00Z", "doi": "10.1136/bcr-2023-256317", "meta_date_publication": "2024 Jan 23", "meta_volume": "17", "meta_issue": "1", "meta_pages": "", "score": 50250.082, "text_hl": "...@<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@Lisinopril@@@ is an ACE inhibitor commonly used in the treatment of @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@cardiovascular and renal disease@@@. ", "citations": {"NLM": "Jarman GL, Webb GJ. Delayed drug-induced liver injury (DILI) and flare of chronic plaque psoriasis secondary to lisinopril use. BMJ Case Rep. 2024 Jan 23;17(1):. PMID: 38262719", "BibTeX": "@article{38262719, title={Delayed drug-induced liver injury (DILI) and flare of chronic plaque psoriasis secondary to lisinopril use.}, author={Jarman GL and Webb GJ}, journal={BMJ Case Rep}, volume={17}, number={1}}"}}, {"_id": "14754654", "pmid": 14754654, "title": "Pemphigus foliaceus: an adverse reaction to lisinopril.", "journal": "J Dermatolog Treat", "authors": ["Patterson CR", "Davies MG"], "date": "2004-01-01T00:00:00Z", "doi": "10.1080/09546630310013379", "meta_date_publication": "2004 Jan", "meta_volume": "15", "meta_issue": "1", "meta_pages": "60-2", "score": 50068.758, "text_hl": "...@<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@Lisinopril@@@ is an angiotensin converting enzyme inhibitor used in the treatment of @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@cardiovascular disease@@@. ", "citations": {"NLM": "Patterson CR, Davies MG. Pemphigus foliaceus: an adverse reaction to lisinopril. J Dermatolog Treat. 2004 Jan;15(1):60-2. PMID: 14754654", "BibTeX": "@article{14754654, title={Pemphigus foliaceus: an adverse reaction to lisinopril.}, author={Patterson CR and Davies MG}, journal={J Dermatolog Treat}, volume={15}, number={1}, pages={60-2}}"}}, {"_id": "29276932", "pmid": 29276932, "title": "[Lisinopril, Amlodipine, Rosuvastatin as a Novel Fixed Combination in the Fight Against Cardiovascular Disease].", "journal": "Kardiologiia", "authors": ["Semenova AE", "Sergienko IV"], "date": "2017-10-01T00:00:00Z", "doi": "10.18087/cardio.2017.10.10044", "meta_date_publication": "2017 Oct", "meta_volume": "57", "meta_issue": "10", "meta_pages": "73-79", "score": 50067.074, "text_hl": "[@<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@Lisinopril@@@, @CHEMICAL_Amlodipine @CHEMICAL_MESH:D017311 @@@Amlodipine@@@, @CHEMICAL_Rosuvastatin_Calcium @CHEMICAL_MESH:D000068718 @@@Rosuvastatin@@@ as a Novel Fixed Combination in the Fight Against @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@Cardiovascular Disease@@@].", "citations": {"NLM": "Semenova AE, Sergienko IV. [Lisinopril, Amlodipine, Rosuvastatin as a Novel Fixed Combination in the Fight Against Cardiovascular Disease]. Kardiologiia. 2017 Oct;57(10):73-79. PMID: 29276932", "BibTeX": "@article{29276932, title={[Lisinopril, Amlodipine, Rosuvastatin as a Novel Fixed Combination in the Fight Against Cardiovascular Disease].}, author={Semenova AE and Sergienko IV}, journal={Kardiologiia}, volume={57}, number={10}, pages={73-79}}"}}, {"_id": "22702239", "pmid": 22702239, "title": "Syntheses and characterization of lisinopril-coated gold nanoparticles as highly stable targeted CT contrast agents in cardiovascular diseases.", "journal": "Langmuir", "authors": ["Ghann WE", "Aras O", "Fleiter T", "Daniel MC"], "date": "2012-07-17T00:00:00Z", "doi": "10.1021/la301694q", "meta_date_publication": "2012 Jul 17", "meta_volume": "28", "meta_issue": "28", "meta_pages": "10398-408", "score": 50064.508, "text_hl": "Syntheses and characterization of @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@-coated gold nanoparticles as highly stable targeted CT contrast agents in @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@cardiovascular diseases@@@.", "citations": {"NLM": "Ghann WE, Aras O, Fleiter T, Daniel MC. Syntheses and characterization of lisinopril-coated gold nanoparticles as highly stable targeted CT contrast agents in cardiovascular diseases. Langmuir. 2012 Jul 17;28(28):10398-408. PMID: 22702239", "BibTeX": "@article{22702239, title={Syntheses and characterization of lisinopril-coated gold nanoparticles as highly stable targeted CT contrast agents in cardiovascular diseases.}, author={Ghann WE and Aras O and Fleiter T and Daniel MC}, journal={Langmuir}, volume={28}, number={28}, pages={10398-408}}"}}, {"_id": "11492990", "pmid": 11492990, "title": "Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study.", "journal": "Eur Heart J", "authors": ["Cleland JG", "Thygesen K", "Uretsky BF", "Armstrong P", "Horowitz JD", "Massie B", "Packer M", "Poole-Wilson PA", "Rydén L", "ATLAS investigators"], "date": "2001-09-01T00:00:00Z", "doi": "10.1053/euhj.2000.2570", "meta_date_publication": "2001 Sep", "meta_volume": "22", "meta_issue": "17", "meta_pages": "1601-12", "score": 50063.52, "text_hl": "AIMS: To determine the sequence of critical @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@cardiovascular@@@ events in the progression of @DISEASE_Heart_Failure @DISEASE_MESH:D006333 @@@heart failure@@@, and whether aetiology or high-dose vs low-dose @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ affected these pathways. ", "citations": {"NLM": "Cleland JG, Thygesen K, Uretsky BF, Armstrong P, Horowitz JD, Massie B, Packer M, Poole-Wilson PA, Rydén L, ATLAS investigators. Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study. Eur Heart J. 2001 Sep;22(17):1601-12. PMID: 11492990", "BibTeX": "@article{11492990, title={Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study.}, author={Cleland JG and Thygesen K and Uretsky BF and Armstrong P and Horowitz JD and Massie B and Packer M and Poole-Wilson PA and Rydén L and ATLAS investigators}, journal={Eur Heart J}, volume={22}, number={17}, pages={1601-12}}"}}, {"_id": "24398888", "pmid": 24398888, "title": "Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial.", "journal": "Nephrol Dial Transplant", "authors": ["Agarwal R", "Sinha AD", "Pappas MK", "Abraham TN", "Tegegne GG"], "date": "2014-03-01T00:00:00Z", "doi": "10.1093/ndt/gft515", "meta_date_publication": "2014 Mar", "meta_volume": "29", "meta_issue": "3", "meta_pages": "672-81", "score": 50059.55, "text_hl": "Serious @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@cardiovascular@@@ events in the @CHEMICAL_Atenolol @CHEMICAL_MESH:D001262 @@@atenolol@@@ group occurred in 16 subjects, who had 20 events, and in the @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ group in 28 subjects, who had 43 events {incidence rate ratio (IRR) 2.36 [95% confidence interval (95% CI) 1.36-4.23, P = 0.001]}. ", "citations": {"NLM": "Agarwal R, Sinha AD, Pappas MK, Abraham TN, Tegegne GG. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrol Dial Transplant. 2014 Mar;29(3):672-81. PMID: 24398888", "BibTeX": "@article{24398888, title={Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial.}, author={Agarwal R and Sinha AD and Pappas MK and Abraham TN and Tegegne GG}, journal={Nephrol Dial Transplant}, volume={29}, number={3}, pages={672-81}}"}}, {"_id": "22144768", "pmid": 22144768, "pmcid": "PMC3229779", "title": "Protective effect of lisinopril on hepatic ischemia/reperfusion injury in rats", "journal": "Indian J Pharmacol", "authors": ["Morsy MA"], "date": "2011-11-01T00:00:00Z", "doi": "10.4103/0253-7613.89820", "meta_date_publication": "2011 Nov", "meta_volume": "43", "meta_issue": "6", "meta_pages": "652-5", "score": 50058.48, "text_hl": "@DISEASE_Reperfusion_Injury @DISEASE_MESH:D015427 @@@Ischemia/reperfusion@@@ (@DISEASE_Reperfusion_Injury @DISEASE_MESH:D015427 @@@I/R) injury@@@ plays a key role in the pathogenesis of @DISEASE_Liver_Failure @DISEASE_MESH:D017093 @@@hepatic failure@@@ in several clinical settings such as liver resection or transplantation. @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@Lisinopril@@@, a widely prescribed drug for various @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@cardiovascular conditions@@@, has been reported to have diverse pharmacological properties. ", "citations": {"NLM": "Morsy MA. Protective effect of lisinopril on hepatic ischemia/reperfusion injury in rats Indian J Pharmacol. 2011 Nov;43(6):652-5. PMID: 22144768", "BibTeX": "@article{22144768, title={Protective effect of lisinopril on hepatic ischemia/reperfusion injury in rats}, author={Morsy MA}, journal={Indian J Pharmacol}, volume={43}, number={6}, pages={652-5}}"}}, {"_id": "17519461", "pmid": 17519461, "title": "Valsartan versus lisinopril or extended-release metoprolol in preventing cardiovascular and renal events in patients with hypertension.", "journal": "Am J Health Syst Pharm", "authors": ["Delea TE", "Taneja C", "Moynahan A", "Thomas SK", "Frech-Tamas F", "Oster G"], "date": "2007-06-01T00:00:00Z", "doi": "10.2146/ajhp060380", "meta_date_publication": "2007 Jun 1", "meta_volume": "64", "meta_issue": "11", "meta_pages": "1187-96", "score": 50057.277, "text_hl": "@CHEMICAL_Valsartan @CHEMICAL_MESH:D000068756 @@@Valsartan@@@ versus @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ or extended-release @CHEMICAL_Metoprolol @CHEMICAL_MESH:D008790 @@@metoprolol@@@ in preventing @<m>DISEASE_Cardiovascular_Diseases</m> @DISEASE_MESH:D002318 @@@cardiovascular and renal events@@@ in @SPECIES_9606 @@@patients@@@ with @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@.", "citations": {"NLM": "Delea TE, Taneja C, Moynahan A, Thomas SK, Frech-Tamas F, Oster G. Valsartan versus lisinopril or extended-release metoprolol in preventing cardiovascular and renal events in patients with hypertension. Am J Health Syst Pharm. 2007 Jun 1;64(11):1187-96. PMID: 17519461", "BibTeX": "@article{17519461, title={Valsartan versus lisinopril or extended-release metoprolol in preventing cardiovascular and renal events in patients with hypertension.}, author={Delea TE and Taneja C and Moynahan A and Thomas SK and Frech-Tamas F and Oster G}, journal={Am J Health Syst Pharm}, volume={64}, number={11}, pages={1187-96}}"}}]}